# Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis

Source: https://onco.cc/trials/nct05004285/  
OnCo record `nct05004285` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Florastamin F-18 run by FutureChem, active.

## Summary

Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis is a phase 3 interventional study registered as NCT05004285 by FutureChem, with 398 participants planned, started 2021-04-28. Conditions listed: High Risk Prostate Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05004285
- Phase: 3
- Setting: A Multi Center, Non-randomized, Open, Phase 3 Study to Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis in Prostate Cancer Risk Groups
- Sponsor: FutureChem
- Enrolled: 398

## Sources

- ClinicalTrials.gov NCT05004285: https://clinicaltrials.gov/study/NCT05004285

## Connected records

- drugs: [Florastamin F-18](https://onco.cc/drugs/florastamin-f18/)
- companies: [FutureChem](https://onco.cc/companies/futurechem/)

---
JSON: https://onco.cc/api/v1/entities/nct05004285.json